FDA cites Advanced Compounding Solutions for insanitary sterile-drug production and CGMP failures after a 2022 inspection.
What happened
FDA inspected the Woburn, MA outsourcing facility from March 21 to April 28, 2022. Investigators found sterile drugs made under insanitary conditions—such as operators resting hands on a hood work surface, blocked first air, inadequate smoke studies, hard-to-clean surfaces, liquid pools, pests, and blocked air returns—plus CGMP (current good manufacturing practice) failures in investigations, complaints, cleaning, and air supply. The company also omitted dosage form on labels for several compounded drugs.
What FDA found
Sterile drug products were prepared under insanitary conditions that could contaminate them, including poor aseptic technique, blocked first air, pests, and liquid on cleanroom floors.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm failed to thoroughly investigate unexplained discrepancies or batch failures.
21 CFR 211.192The firm failed to establish and follow adequate complaint-handling procedures and did not investigate a cited complaint.
21 CFR 211.198(a)The firm failed to establish and follow written procedures to prevent microbiological contamination, including validation of aseptic and sterilization processes.
21 CFR 211.113(b)The firm failed to establish an adequate system for cleaning and disinfecting rooms and equipment used for aseptic conditions.
21 CFR 211.42(c)(10)(v)The firm failed to provide an adequate air supply filtered through high-efficiency particulate air (HEPA) filters under positive pressure in aseptic processing areas.
21 CFR 211.42(c)(10)(iii)
What FDA wants
FDA tells the company to promptly correct the violations, investigate their causes, and prevent recurrence, and strongly recommends a comprehensive assessment of its aseptic operations by a third-party sterile drug manufacturing expert. No response deadline is stated in the provided letter.
Who should pay attention
- other 503B outsourcing facilities making sterile drugs
- hospitals and clinics that buy compounded sterile products
- compounding pharmacy quality teams
This is a summary. Read the original letter on fda.gov.